A stable quarter with growth and new agreements

MAR

1 July-30 September

  • Net sales reached SEK 3,8 (3,7) million
  • Loss after taxes SEK -2,1 (-1,7) million
  • Earnings per share were SEK -0,04 SEK (-0,03)
  • Cash and equivalents were 15,9 (16,7) million

Significant events during period

  • The company carried out a rights issue which brought the company approximately SEK 19.8 million in capital before issue costs
  • A letter of intent regarding the distribution agreement for China is signed
  • Agreement with Capio Specialistmottagning, Lund
  • Distribution agreement signed for Brazil

1 January-30 September

  • Net sales reached SEK 11,9 (12,1) million
  • Loss after taxes SEK -8,0 (-5,7) million
  • Earnings per share were SEK -0,15 SEK (-0,12)

Significant events after the end of the period

  • Results for the registry study on prostate cancer are presented at the Urologidagarna in Malmö by one of the authors
  • Distribution agreement signed for Spain
Key figures



(SEK MILLION)Jan-Sep
2022
Jan-Sep
2021
Jan-Sep
2020
Jan-Sep
2019
Net sales11,912,18,89,5
Gross margin, %77857167
Operating profit/loss-7,7-5,6-6,2-8,1
Cash flow from operating activities-13,0-6,3-6,2-6,6
Average number of employees7755

“There is no longer any doubt that we have world-class products”

Johan Wennerholm
CEO, ProstaLund AB (publ)

Please see attached PDF for full report.

Datum 2022-10-21, kl 08:15
Källa MFN
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet